Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | DHFR | P00374 | 1/20 | 0.48 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.43 |
| ▸ | VCAM1 | P19320 | 6/20 | 0.43 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.41 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | ALPL | P05186 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31587453 | 0.82 | ALDH1A1 (0.46) | MAPTMEN1ALDH1A1KMT2AVCAM1 | |
| SCHEMBL5311953 | 0.82 | MAPT (0.60) | MAPTMEN1ALDH1A1KMT2ADHFR | |
| SCHEMBL23850830 | 0.82 | ALDH1A1 (0.46) | MAPTMEN1ALDH1A1KMT2AVCAM1 | |
| SCHEMBL30750463 | 0.79 | TDP1 (0.47) | MAPTMEN1ALDH1A1KMT2AVCAM1 | |
| SCHEMBL27176841 | 0.79 | TDP1 (0.47) | MAPTMEN1ALDH1A1KMT2AVCAM1 | |
| SCHEMBL23327052 | 0.79 | MEN1 (0.44) | MAPTMEN1ALDH1A1KMT2AALPL | |
| SCHEMBL1068602 | 0.79 | TDP1 (0.47) | MAPTMEN1ALDH1A1KMT2ADHFR | |
| SCHEMBL703287 | 0.77 | AHR (0.48) | MAPTMEN1ALDH1A1KMT2AADORA1 | |
| SCHEMBL5992360 | 0.77 | VCAM1 (0.60) | MAPTMEN1ALDH1A1KMT2ADHFR | |
| SCHEMBL4412067 | 0.77 | MAPT (0.50) | MAPTMEN1ALDH1A1KMT2ADHFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090203692-A1 | NOVEL CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION | 2009-08-13 | — | — | US | disclosed |
| EP-1885362-A2 | NOVEL CHEMICAL COMPOUNDS | Smithkline Beecham Corporation (US) | 2008-02-13 | — | — | EP | disclosed |
| WO-2006127458-A2 | NOVEL CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2006-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203692-A1 | NOVEL CHEMICAL COMPOUNDS | HIPK3, HIPK1, HIPK4 | MAPT 1880/4885MEN1 3889/4885ALDH1A1 4089/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.